Peptic Ulcer Disease: An In-Depth Analysis of Pathophysiology, Symptoms, Diagnosis, and Cutting-Edge Treatments
Abstract
Peptic Ulcer Disease (PUD) is a common stomach condition where ulcers form in the stomach lining or the upper part of the small intestine. It is mainly caused by a bacteria called Helicobacter pylori (H-pylori). H-pylori infection and long-term use of NSAIDs can cause this condition. This detailed study looks at the causes, symptoms, risks, signs, ways to diagnose, and treatments for PUD. The sickness is characterized by symptoms like pain in the upper abdomen, pain after eating, pain at night, and feeling better after eating or taking antacids. Less common symptoms of stomach ulcers may include anaemia from bleeding in the stomach, weight loss due to loss of appetite, and vomiting from complications like pyloric stenosis. The diagnosis of stomach ulcers often requires endoscopy to directly see and take samples of ulcers to rule out cancer and confirm H. pylori infection. H-pylori infection. Advances in medical tests have made it easier to detect stomach ulcers. Treatment options include medicines like proton pump inhibitors (PPIs) and antibiotics for H. pylori. Treatment for H-pylori infection to eliminate the bacteria and lifestyle changes to prevent ulcers from coming back. Even with these improvements, there are still problems, especially with the increasing levels of bacteria that are resistant to antibiotics. Ulcers caused by H-pylori bacteria and NSAIDs need to be managed. This study shows how important it is to diagnose correctly and treat effectively to avoid problems like bleeding, perforation, and gastric outlet obstruction. Continuous research is important to tackle new problems with antibiotic resistance and to create better ways to manage Peptic Ulcer Disease. This will help lessen its impact on health and healthcare systems worldwide
Keywords:
Peptic Ulcer Disease (PUD), Helicobacter pylori, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Gastric Ulcer,, Duodenal Ulcer, Proton Pump Inhibitors (PPIs), Endoscopy, Antibiotic Resistance,DOI
https://doi.org/10.5281/zenodo.20437366References
Lanas, A., & Chan, F. K. (2017). Peptic ulcer disease. The Lancet, 390(10094), 613-624.
Lanas, A., & Chan, F. K. (2017). Peptic ulcer disease. The Lancet, 390(10094), 613-624.
Malfertheiner, P., Chan, F. K., & McColl, K. E. (2009). Peptic ulcer disease. The Lancet, 374(9699), 1449-1461.
Sung, J. J., Kuipers, E. J., & El-Serag, H. B. (2009). Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary Pharmacology & Therapeutics, 29(9), 938-946.
Gustavsson S and Nyren O (1989) Time trends in peptic ulcer surgery, 1956 to 1986. A nation-wide survey in Sweden. Ann Surg 210: 704–709
Sach G (1997) Proton pump inhibitors and acid related diseases. Pharmacotherapy 17: 22–37
Sonnenberg A (1985) Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol Suppl 110: 11–24
Sonnenberg A and Everhart JE (1996) The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 86: 200–205
Sandler RS et al. (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500–1511
Peterson, W. L. (1991). Helicobacter pylori and peptic ulcer disease. New England Journal of Medicine, 324(15), 1043-1048.
Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and non aspirin nonsteroidal anti inflammatory drugs. Am J Epidemiol. 2004;159(1):23–31.
Suerbaum, S., & Michetti, P. (2002). Helicobacter pylori infection. New England Journal of Medicine, 347(15), 1175-1186.
Hatakeyama, M. (2004). Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nature Reviews Cancer, 4(9), 688-694.
Ruggiero, P. (2010). Helicobacter pylori virulence factors. Current Opinion in Microbiology, 13(1), 44-49.
Wallace, J. L. (2008). Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiological Reviews, 88(4), 1547-1565.
Ko, J. K., Cho, C. H., & Lam, S. K. (1996). Role of smoking, alcohol, and diet in the development of peptic ulcer disease: An update. Postgraduate Medical Journal, 72(843), 469-473.
Bode, C., & Bode, J. C. (1997). Alcohol's role in gastrointestinal tract disorders. Alcohol Health & Research World, 21(1), 76-83.
Sonnenberg, A. (1985). Dyspeptic symptoms and peptic ulcer disease: a comparative study. Gut, 26(11), 1133-1141.
Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993;88:2038-43)
Kurata, J. H., & Haile, B. M. (1984). Epidemiology of peptic ulcer disease. Clinics in Gastroenterology, 13(2), 289-307.
Ramakrishnan, K., & Salinas, R. C. (2007). Peptic ulcer disease. American Family Physician, 76(7), 1005-1012.
Borum, M. L. (1996). Peptic ulcer disease: a review of pathophysiology, diagnosis, and treatment. Digestive Diseases, 14(3), 142-148.
Fischbach, L., Evans, E. L., & Peppercorn, M. A. (2002). American Gastroenterological Association technical review on the management of Helicobacter pylori infection. Gastroenterology, 123(1), 179-190.
Sonnenberg, A., Steinkamp, U., & Weise, A. (1986). Clinical epidemiology of peptic ulcer disease: a 10-year study of admissions and mortality. Gastroenterology, 90(1), 167-173.
Boey, J., Branicki, F. J., & Wong, J. (1982). Perforated duodenal ulcers: an analysis of the prognostic factors. American Journal of Surgery, 144(1), 99-104.
Lanas, A., & Chan, F. K. (2017). Peptic ulcer disease. The Lancet, 390(10094), 613-624.
Graham DY et al. (1988) Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the 13C urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 157: 777–78
Xia HH et al. (2001) Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in western Sydney between 1990 and 1998. Dig Dis Sci 46: 2716–2723 15 Perez-Aisa MA et al. (2005) Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 65–72
Ford A et al. (2004) Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. The Cochrane Database of Systematic Reviews. Issue 4, Art. No. CD003840.pub2
Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756–1780.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239.
Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2006 [CD005415].
Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010(7) [CD005415].
Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, DominguezMunoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther. 2004;19(6):617– 629.
Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–2038.
Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701–710. 30. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104 (3):728–738.
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.
Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14 (1):179.
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–950.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715.
Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient protonpump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84 (2):102–113.
Gurusamy KS, Pallari E. Medical versus surgical treatment for refractory or recurrent peptic ulcer. Cochrane Database Syst Rev. 2016;3: CD011523.
Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345–360 [quiz 361].
Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381(9882):2033–2.
Published
Abstract Display: 14 
PDF Downloads: 4 PDF Downloads: 1 PDF Downloads: 1 PDF Downloads: 2 Issue
Section
Copyright (c) 2026 Gazi Musaib Ul Islam, Obaid Ahmad Lone, Dr. Tanya Sharma, Dr. Gaurav Sharma, Mr. Pankaj Chasta (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
